Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden

Grönhagen, Carina M; Fored, C. Michael; Linder, Marie; Granath, Fredrik; Nyberg, Fred

doi:10.1111/j.1365-2133.2012.10969.x

Cited by 133 publications

(118 citation statements)

References 79 publications

Supporting

Mentioning

107

Contrasting

Unclassified

Order By: Relevance

“…Moreover, we registered no significant difference compared to controls. Besides that, more than one third of SCLE cases seem to be drug induced 27 These data suggest that other factors -such as drugs or immunological ones -might be involved in the pathogenesis of this cutaneous LE entity.…”

Section: Does Smoking Behavior Differ In Cutaneous Variants Of Le?mentioning

confidence: 80%

Smoking is highly associated with discoid lupus erythematosus and lupus erythematosus tumidus: analysis of 405 patients

Böckle

Sepp

2014

Lupus

View full text Add to dashboard Cite

show abstract

Section: Does Smoking Behavior Differ In Cutaneous Variants Of Le?mentioning

confidence: 80%

Smoking is highly associated with discoid lupus erythematosus and lupus erythematosus tumidus: analysis of 405 patients

Böckle

Sepp

2014

Lupus

View full text Add to dashboard Cite

show abstract

“…In addition to this, one can search for Anti-La [6] [8] [11], which shows positivity when above 10.0 U/mL, and the patient has a value lower than 7.0 U/mL, which can also be present in the disease and comes according to the literature, because Anti-La is found in only approximately 10% of lupus carriers [6] Treatment can be done by topical sunscreens, steroids and calcineurin inhibitors, while more severe conditions can be treated with hydroxychloroquine and systemic steroids [28] [29] [30] [31]. The patient was duly approached, being treated with hydroxychloroquine 400 mg/day and together with the use of sunscreen.…”

Section: Discussionmentioning

confidence: 99%

Subacute Cutaneous Lupus Erythematosus in Older Man: Case Report

Martins¹,

Miguel²,

Anjos³

et al. 2017

JBM

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is an autoimmune disease that affects mainly women, presents several clinical manifestations and has no known exact cause. The skin is one of the organs that can be affected, with subacute cutaneous lupus erythematosus (SCLE) being one of the classifications according to cutaneous lupus erythematosus lesions. SCLE is commonly found in young to middle age women and carries characteristics related to sun exposure. In this report, there is a rare case of a male and elderly patient that presents SCLE subgroup initially asymptomatic, with subsequent appearance of macular skin lesions and vitiligo appearance. This is an important case to alert health professionals that the disease can manifest itself and open its clinical profile even in patients of sex and unusual ages.

show abstract

“…Moreover, in a Swedish population-based matched case-control study of 234 patients with SCLE, 65 received PPI. The odds ratio for developing SCLE after treatment with PPI was 2.9 [9]. …”

Section: Discussionmentioning

confidence: 99%

Subacute Cutaneous Lupus Erythematosus Induced and Exacerbated by Proton Pump Inhibitors

Almebayadh

Régnier‐Rosencher²,

Carlotti³

et al. 2013

Dermatology

View full text Add to dashboard Cite

Background: Subacute cutaneous lupus erythematosus (SCLE) can be induced by numerous drugs. We report 3 cases of SCLE induced by proton pump inhibitors (PPIs). Objective: To highlight a rare cutaneous side effect induced by a frequently prescribed drug such as a PPI. Case Reports: Case 1 was a 30-year-old man who developed multiple annular plaques over the trunk and lower limbs 1 month after the initiation of pantoprazole. Antinuclear antibodies (ANA) were positive with anti-Ro/SSA and anti-La/SSB antibodies, and histology confirmed the diagnosis. Clinical improvement was achieved 8 weeks after the discontinuation of pantoprazole and the introduction of a treatment combining topical steroids and hydroxychloroquine. Lesions relapsed when pantoprazole was accidentally rechallenged. The second case was a 31-year-old woman, 28 weeks pregnant, who presented erythematous annular plaques over the trunk 7 weeks after starting esomeprazole. ANA and anti-Ro/SSA antibodies were positive, and the histology was compatible with SCLE. Fetal ultrasound was normal. She was treated with topical and oral steroids and hydroxychloroquine. Clinical improvement was achieved 4 weeks after the discontinuation of esomeprazole. The third case was a 57-year-old woman with systemic erythematosus lupus presenting annular and psoriasiform lesions on the trunk for 15 months. She was treated successively with hydroxychloroquine, azathioprine, mycophenolate mofetil and methotrexate with prednisone. A review of her drug history revealed the introduction of omeprazole a few weeks before the first appearance of skin lesions and omeprazole was contraindicated. Conclusion: SCLE should systematically be suspected in case of eruption after the introduction of PPI. The risk of fetal cardiac complications is important in pregnant women.

show abstract

Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden

Cited by 133 publications

References 79 publications

Smoking is highly associated with discoid lupus erythematosus and lupus erythematosus tumidus: analysis of 405 patients

Smoking is highly associated with discoid lupus erythematosus and lupus erythematosus tumidus: analysis of 405 patients

Subacute Cutaneous Lupus Erythematosus in Older Man: Case Report

Subacute Cutaneous Lupus Erythematosus Induced and Exacerbated by Proton Pump Inhibitors

Contact Info

Product

Resources

About